Results 111 to 120 of about 489 (130)
Some of the next articles are maybe not open access.
Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of Aficamten
Current Problems in CardiologyHypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy (LVH), which can lead to left ventricular outflow tract (LVOT) obstruction. Traditional treatments often provide limited symptom relief and may not adequately reduce the LVOT gradient.
Emmanuel, Kokori +9 more
openaire +2 more sources
Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis
European Heart JournalAbstract Background Aficamten is a next-in-class, oral, selective cardiac myosin inhibitor targeting the hypercontractility underlying hypertrophic cardiomyopathy (HCM). It relieves left ventricular outflow tract obstruction, improves exercise capacity, symptoms, quality of life, and cardiac ...
A Masri +14 more
openaire +1 more source
Aficamten for Obstructive Hypertrophic Cardiomyopathy
New England Journal of MedicineJorge, Pedreira-Bouzas +2 more
openaire +3 more sources
Auch Aficamten (Myosininhibitor) hocheffektiv und sicher bei HOCM
Aktuelle Kardiologie, 2023openaire +1 more source
Aficamten reduces symptoms in obstructive hypertrophic cardiomyopathy
Nature Reviews Cardiologyopenaire +2 more sources
Aficamten in the treatment of obstructive hypertrophic cardiomyopathy
Future CardiologyDanish Saleh +2 more
openaire +1 more source
Aficamten reduces cardiac contractility by modifying the actomyosin interaction
Nature Cardiovascular ResearchFarid Moussavi-Harami, Michael Regnier
openaire +1 more source
Aficamten in Hypertrophic Cardiomyopathy
Journal of the American College of Cardiologyopenaire +1 more source